Acalabrutinib is a second-generation BTK inhibitor approved by the FDA for treating patients with refractory MCL on the basis of the ACE LY-004 trial (ClinicalTrials.gov identifier: NCT02213926). The gene discussed is BTK; the disease is mantle cell lymphoma.